Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Buprenorphine

FDA-approved product (film, extended release, transdermal), marketed as Brixadi, Buprenorphine, Butrans and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Buprenorphine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic pain
  • Drug dependence
  • Opioid dependence
  • Opioid use disorder
  • Overdose
  • Pain
  • Substance abuse

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Oripavine derivatives; Drugs used in opioid dependence
FDA pharmacologic class
Partial Opioid Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Buprenorphine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not docked: the structure could not be prepared for dockingdetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not docked: the structure could not be prepared for dockingdetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not docked: the structure could not be prepared for dockingdetails

Dihydrofolate reductase ↗ (MRSA)

Not docked: the structure could not be prepared for dockingdetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Buprenorphine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

    NCT03996694 · start 2019-07-23

    Registered record
    Registry ID
    NCT03996694
    Conditions
    Respiratory Depression
    Interventions
    Belbuca 300 µg; Belbuca 600 µg; Belbuca 900 µg; Oxycodone 30 mg; Oxycodone 60 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-07-23
    Completion
    2019-10-27
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Depression
    InterventionBelbuca 300 µg; Belbuca 600 µg; Belbuca 900 µg; Oxycodone 30 mg +2 more
    PhasePhase 1
    Registry statusCompleted

  • MINDFUL-OBOT: Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment

    NCT03798431 · start 2018-12-11

    Registered record
    Registry ID
    NCT03798431
    Conditions
    Opioid-use Disorder; Anxiety; Depression; Stress Related Disorder
    Interventions
    M-ROCC
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-12-11
    Completion
    2020-02-03
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-use Disorder; Anxiety; Depression; Stress Related Disorder
    InterventionM-ROCC
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • Optimal Treatment of Veterans With PTSD and Comorbid OUD

    NCT03605342 · start 2018-10-01

    Registered record
    Registry ID
    NCT03605342
    Conditions
    Post-Traumatic Stress Disorders; Opiate Use Disorder
    Interventions
    Buprenorphine; Cognitive Processing Therapy (CPT); Individual Drug Counseling (IDC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-10-01
    Completion
    2023-04-14
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Stress Disorders; Opiate Use Disorder
    InterventionBuprenorphine; Cognitive Processing Therapy (CPT); Individual Drug Counseling (IDC)
    PhasePhase 2
    Registry statusTerminated

  • Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

    NCT03608696 · start 2018-08-29

    Registered record
    Registry ID
    NCT03608696
    Conditions
    Neonatal Abstinence Syndrome; Neonatal Opiate Withdrawal Syndrome
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-08-29
    Completion
    2019-07-11
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Abstinence Syndrome; Neonatal Opiate Withdrawal Syndrome
    InterventionBuprenorphine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Smoking Cessation & Opioid Dependence Treatment Integration

    NCT02854800 · start 2016-07-08

    Registered record
    Registry ID
    NCT02854800
    Conditions
    Smoking Cessation; Opioid Related Disorders
    Interventions
    varenicline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-07-08
    Completion
    2017-04-10
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking Cessation; Opioid Related Disorders
    Interventionvarenicline
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

    NCT02696434 · start 2016-04

    Registered record
    Registry ID
    NCT02696434
    Conditions
    Opioid Use Disorder
    Interventions
    Naltrexone; Placebo; Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04
    Completion
    2017-11-30
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder
    InterventionNaltrexone; Placebo; Buprenorphine
    PhasePhase 3
    Registry statusCompleted

  • Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

    NCT02537574 · start 2015-08

    Registered record
    Registry ID
    NCT02537574
    Conditions
    Opioid Use Disorder
    Interventions
    NTX/BUP; NTX/PBO-B; PBO-N/PBO-B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08
    Completion
    2017-01-09
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder
    InterventionNTX/BUP; NTX/PBO-B; PBO-N/PBO-B
    PhasePhase 3
    Registry statusCompleted

  • Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?

    NCT02162121 · start 2014-05

    Registered record
    Registry ID
    NCT02162121
    Conditions
    Hip Replacement Arthroplasty
    Interventions
    Continuous lumbar plexus: stimulating catheter; Spinal Anesthesia; Local anesthetic infusion; Intravenous analgesia; Opioids rescue analgesia; Mepivacaine 1%; Levobupivacaine 0,5%; Ropivacaine 0,2%; Ketorolac 30mg; Buprenorphine 0,2mg; Stimulong, Pajunk, Germany.; Continuous lumbar plexus: non-stimulating catheter
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-05
    Completion
    2016-10
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHip Replacement Arthroplasty
    InterventionContinuous lumbar plexus: stimulating catheter; Spinal Anesthesia; Local anesthetic infusion; Intravenous analgesia +8 more
    PhasePhase 4
    Registry statusCompleted

  • Using mHealth to Aid Opioid Medication Adherence Pilot Study

    NCT02017041 · start 2014-01

    Registered record
    Registry ID
    NCT02017041
    Conditions
    Opioid Dependence
    Interventions
    Medsignals; smartphone app
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-01
    Completion
    2014-06
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Dependence
    InterventionMedsignals; smartphone app
    PhaseNot recorded
    Registry statusCompleted

  • Improving Buprenorphine Detoxification Outcomes With Isradipine

    NCT01895270 · start 2013-10

    Registered record
    Registry ID
    NCT01895270
    Conditions
    Opioid Dependence
    Interventions
    Isradipine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2016-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Dependence
    InterventionIsradipine; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy

    NCT02247648 · start 2013-06

    Registered record
    Registry ID
    NCT02247648
    Conditions
    Pain; Vertigo; Nausea; Pruritus
    Interventions
    tramadol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Vertigo; Nausea; Pruritus
    Interventiontramadol; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects

    NCT01675167 · start 2012-09

    Registered record
    Registry ID
    NCT01675167
    Conditions
    Low Back Pain
    Interventions
    Buprenorphine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-06
    Enrolment
    815

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow Back Pain
    InterventionBuprenorphine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

    NCT01637922 · start 2012-08

    Registered record
    Registry ID
    NCT01637922
    Conditions
    Hepatitis C
    Interventions
    BI 201335; BI 201335
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-08
    Completion
    2012-11
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionBI 201335; BI 201335
    PhasePhase 1
    Registry statusCompleted

  • Effects of Low Dose Buprenorphine on Recovery After Hip or Knee Arthroplasty

    NCT02575664 · start 2012-08

    Registered record
    Registry ID
    NCT02575664
    Conditions
    Pain; Osteoarthritis
    Interventions
    Buprenorphine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-08
    Completion
    2015-10
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Osteoarthritis
    InterventionBuprenorphine; Placebo
    PhasePhase 4
    Registry statusCompleted